This article has been updated with a correction to the current market penetration for Cologuard. The correct figure is 1 percent, not 42 percent as originally reported.

NEW YORK (GenomeWeb) – Leerink on Monday initiated coverage of molecular diagnostics firm Exact Sciences with an Outperform rating and a 12-month $30 price target on the company's stock price.